Clinical trials: Covid19- Coronavirus- Sars-cov-2
Pregnancy, Covid19
Prevalence of COVID-19 (Coronavirus Disease 19) in Pregnant Women on Labor in a Public Hospital in Chile (COroNavirus diSease Covid-19 pandEmic iN ChilE)
This study aim is to assess the prevalence of SARS-COV-2 in unselected pregnant women on labour (or a predictable delivery during next 24 hours), their outcome and sociodemographic conditions.
- Conditions
- Pregnancy, Covid19, Labor (Obstetrics)--Complications, Demography
- Trial name
- CONSCIENCE (NCT04551690)
- Where
- Chile
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Hospital San Juan de Dios, Santiago
SARS CoV 2 Infection
Inhibition of Bradykinin in COVID-19 Infection With Icatibant
There is excess accumulation of bradykinin during symptomatic SARS CoV-2 lung infection. Bradykinin causes oedema in the lung, with reduced oxygen. It also causes vasodilation, hypotension and cytokine release.
- Trial name
- ICASARS (NCT05407597)
- Testing
- Icatibant, 0.9% Sodium Chloride Injection
- Where
- United Kingdom
- Volunteers
- 32 people
- Sponsor
- Belfast Health and Social Care Trust
SARS-CoV-2 Infection, COVID19
Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years
This is a 4 dose study with 124 participants (7 adults ,117 children). Adults are considered to be participants 18 years of age or older. Participants are going to be enrolled based on conditions that make them immunocompromised.
- Trial name
- NCT04895982
- Testing
- BNT162b2
- Where
- 29 sites in United States, Brazil and 2 more
- Volunteers
- 124 people
- Sponsor
- BioNTech SE
COVID-19
IH Convidecia as Second Booster Dose Against Breakthrough Infections
This will be a randomized single-blind controlled trial to determine the immunogenicity, efficacy and safety of IH Convidecia (CanSino), as a second booster vaccination against Omicron and other emerging VOCs to prevent…
- Trial name
- NCT05517642
- Testing
- Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH), mRNA vaccine BNT162b2 (Pfizer)
- Where
- Malaysia
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
COVID-19, Therapeutic Vaccine
COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement
To date, there is no vaccine or treatment with proven efficiency against COVID-19, and the transmissibility of the SARS-CoV-2 virus can be inferred by its identification in the oro-nasopharynx.
- Conditions
- COVID-19, Therapeutic Vaccine, BCG, SARS-CoV 2
- Trial name
- BATTLE (NCT04369794)
- Testing
- BCG
- Where
- Brazil
- Volunteers
- 400 people
- Sponsor
- University of Campinas, Brazil
Covid19, Surgery--Complications
Impact of the COVID-19 Pandemic on the Surgical Activity of Bellvitge University Hospital
COVID-19 has been a challenge for hospitals; there was an obvious need to reconvert many spaces in specific areas to attend this pathology, without forgetting the attention to other pathologies and surgery.
- Conditions
- Covid19, Surgery--Complications, Nosocomial Infection
- Trial name
- NCT04780594
- Testing
- The study evaluates all surgical patients operated, both elective scheduled and emergent cases
- Where
- Spain
- Volunteers
- 2,530 people
- Sponsor
- Hospital Universitari de Bellvitge
Covid19
Hyperbaric Oxygen for Long COVID-19 Pulmonary Sequela
This is a pilot study in 24 subjects where half will be randomized to 10 treatments with hyperbaric oxygen (HBO). It will primarily study pulmonary sequelae with imaging and physiological measurements (low dose chest computer…
- Trial name
- NCT04905888
- Testing
- Hyperbaric oxygen therapy
- Where
- United States
- Sponsor
- Peter Lindholm
SARS-CoV-2 Infection, COVID-19
To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older
Results will be submitted, however please note that data are not yet available for all serology outcome measures. This will be a Phase 2/3, randomized, placebo-controlled, observer-blind study evaluating the safety, tolerability…
- Conditions
- SARS-CoV-2 Infection, COVID-19, Maternal Immunization
- Trial name
- NCT04754594
- Testing
- BNT162b2
- Where
- 90 sites in United States, Brazil and 3 more
- Volunteers
- 726 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
SARS-CoV-2, COVID-19
Epidemiology, Immunology and Clinical Characteristics of COVID-19 (EPIC3)
The purpose of this research is to gather information to answer questions about the Coronavirus Disease 2019 (COVID-19) which is caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection.
- Trial name
- EPIC3 (NCT05764083)
- Where
- United States
- Volunteers
- 2,824 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
SARS-CoV-2 Infection
SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Infusion
This is the first-in-human phase 1/2a trial of the intravenous administration of the SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c in healthy volunteers and SARS-CoV-2-infected individuals.
- Trial name
- NCT04631666
- Testing
- DZIF-10c
- Where
- Germany
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- University of Cologne
Critical Confirmed Coronavirus Disease (COVID)-19
A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19
The purpose of this study is to evaluate the clinical response of sirukumab (administered as a single intravenous dose) plus standard of care (SOC) compared to placebo plus SOC in COVID-19.
- Trial name
- NCT04380961
- Testing
- Sirukumab, Standard of Care (SOC)
- Where
- 16 sites in United States
- Volunteers
- 212 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Sars-CoV2
Contribution of a Prone Team in Intensive Care During the Covid-19 Epidemic
SARS-CoV-2 induced by COVID 19, involved the hospitalization of 101,932 patients in France, including 4,007 in intensive care (source: Santé Publique France).
- Trial name
- COVID-PRONE (NCT04438941)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
Coronavirus Infection
Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia
In early December 2019, cases of pneumonia of unknown origin were identified in Wuhan, China. The causative virus was called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- COP-COVID-19 (NCT04358783)
- Testing
- Plasma, Best Available Therapy
- Where
- Mexico
- Volunteers
- 31 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Pulmonary Fibrosis, Interstitial Lung Disease
The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19
This is a collaborative study between Icahn School of Medicine at Mount Sinai, Boehringer Ingelheim Pharmaceuticals and up to 9 other clinical centers across the US to determine the effect of nintedanib on slowing the rate of…
- Conditions
- Pulmonary Fibrosis, Interstitial Lung Disease, Respiratory Disease
- Trial name
- ENDCOV-I (NCT04619680)
- Testing
- Nintedanib
- Where
- 7 sites in United States
- Volunteers
- 103 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Novel Coronavirus Infectious Disease (COVID-19)
The Clinical Study of Carrimycin on Treatment Patients With COVID-19
The novel coronavirus infectious disease ( COVID-19") induced by novel coronavirus(SARS-CoV-2) in December 2019 has outbreaked in Wuhan. It may lead to epidemic risk in global.
- Trial name
- NCT04286503
- Testing
- Carrimycin, lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate, basic treatment
- Volunteers
- 520 people
- Sponsor
- Beijing YouAn Hospital
Covid19
Antigen Rapid Test Screening to Prevent SARS-CoV-2 Transmission (COVID-19) at Mass Gathering Events.
To investigate the impact of rapid antigen testing for Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2), the investigators plan to conduct a large trial to assess the impact of using rapid tests to screen people…
- Trial name
- NCT04898127
- Testing
- SARS-CoV-2 antigen rapid test
- Sponsor
- Norwegian Institute of Public Health
Acute Respiratory Distress Syndrome, COVID-19 Pneumonia
Double-blind, Randomized, Controlled Clinical Trial to Assess Efficacy of MSC in Patients With COVID-19 ARDS
A double-blind, randomized, controlled, clinical trial to evaluate the efficacy and safety of MSC (mesenchymal stromal cells) intravenous administration in patients with COVID-induced ARDS compared to a control arm.
- Trial name
- NCT04615429
- Testing
- Mesenchymal stromal cells
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Cristina Avendaño Solá
COVID-19, Thrombosis Embolism
The Effect of Dexamethasone 12 mg vs 6 mg on Thromboembolic Events in Patients With Critical COVID-19
Thromboembolisms (TEs) in patients with critical COVID-19 has been reported to be three times higher than for other critically ill patients. Immunothrombosis has been proposed as a plausible mechanism for COVID-19 coagulopathy.
- Conditions
- COVID-19, Thrombosis Embolism, Bleeding
- Trial name
- NCT05195242
- Testing
- Dexamethasone
- Where
- Sweden
- Volunteers
- 445 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Long COVID, Post-COVID-19 Condition
Mitochondrial Function in Peripheral Blood Mononuclear Cells, Muscle, and Skin of Long COVID Patients
Mitochondria are structures inside cells that are responsible for producing energy from nutrients through a series of steps, using oxygen.
- Trial name
- MitoLoCo (NCT07134673)
- Where
- Belgium
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
Patients With Cancer, Vaccine Reaction
Safety and Immunogenicity of Prime-boost Vaccination of SARS-CoV-2 in Patients With Cancer
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused a global pandemic since late 2019 that resulted in more than 360 million population infection.
- Conditions
- Patients With Cancer, Vaccine Reaction, COVID-19
- Trial name
- NCT05273541
- Testing
- Coronavirus vaccination
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Beijing 302 Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.